China's artificial intelligence-driven healthcare sector is advancing rapidly, but persistent legal and ethical uncertainties around data compliance, algorithmic governance, and the boundaries of medical practice continue to shadow its progress, according to reports. Whether AI can fundamentally transform the future of medicine in China will depend, experts say, on how stakeholders navigate the balance between opportunity and risk.

Regulatory Milestone: AI Enters Pricing Framework

In a landmark policy move, China's National Healthcare Security Administration issued guidance in December 2025 formally classifying 'AI-assisted diagnosis' as an extended item within pathological diagnosis. The directive incorporated this classification into the official pricing framework for pathological diagnostic services — a signal that regulators are beginning to treat AI not as an experimental tool, but as a billable, accountable component of clinical care.

Where AI Is Being Deployed

Alan Zhou, head of the life sciences and healthcare practice at Global Law Office, identifies four primary areas where domestic AI healthcare companies are currently concentrating their products and services: clinical decision support, medical imaging, health management and patient-facing services, and drug discovery. According to Zhou, these directions respond to practical demands for improved diagnostic efficiency and optimised health management, while deliberately sidestepping higher-risk segments of medical practice — offering what he describes as a relatively prudent path to deployment.

Data Compliance: The Central Risk

The sensitivity of medical data makes compliance not merely a regulatory formality but, as industry observers note, a baseline requirement for survival in the AI healthcare sector. Zhou identifies data sourcing and its legality as a core difficulty for companies operating in this space.

'The development and deployment of AI technology requires the use of vast quantities of data for training, and data in the medical and pharmaceutical fields frequently involves the sensitive personal information of patients and clinical trial participants,' Zhou said. 'As data usage demands grow rapidly alongside technological advancement, regulatory enforcement centred on informed consent under the Personal Information Protection Law is simultaneously intensifying.'

Unanswered Questions and the Road Ahead

Beyond data sourcing, broader questions around algorithmic governance — including how AI decisions are audited, contested, or overridden by clinicians — remain largely unresolved in China's regulatory architecture. The gap between laboratory performance and real-world clinical deployment continues to be a structural challenge across the sector. Notably, this tension is not unique to China; similar debates are unfolding globally as AI diagnostic tools seek regulatory clearance in the US, EU, and India. What distinguishes China's situation is the pace of domestic deployment combined with a still-evolving compliance environment. How companies unlock their technological potential within that framework will likely define the sector's trajectory over the next decade.